Drugs / Japanese Encephalitis alive vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02643433 | Aug 2015 → Jun 2016 | Japanese encephalitis, measles, rubella | Centers for Disease Control and Prevention, China | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Japanese Encephalitis alive vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02643433 ↗ |
| Known as | LJEV | “Enrolled infants were randomly assigned (1:1) to receive either measles-rubella vaccine and LJEV simultaneously (measles-rubella plus LJEV group) or measles-rubella vaccine...” PMID 30833160 ↗ Mar 2019 |
| Modality | Vaccine | “A live attenuated vaccine (LJEV) manufactured in China” NCT02643433 ↗ |
| Route | Subcutaneous | “be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm” NCT02643433 ↗ |